|
|
||||||||||
|
J Am Coll Cardiol, 2001; 38:194-198 © 2001 by the American College of Cardiology Foundation |




* Department of Medicine, Division of Cardiology, Albert Einstein College of Medicine, Bronx, New York, USA
Department of Developmental and Molecular Biology, the Albert Einstein College of Medicine, Bronx, New York, USA
Division of Cardiology, Beaujon Hospital, Clichy, France
Manuscript received May 23, 2000; revised manuscript received March 2, 2001, accepted March 23, 2001.
Reprint requests and correspondence: Dr. Thierry H. LeJemtel, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Forcheimer. G-44, Bronx, New York 10461
lejemtel{at}aecom.yu.edu
| Abstract |
|---|
|
|
|---|
We sought to determine whether the benefit of training for vasodilation in the skeletal muscle vasculature of patients with chronic heart failure (CHF) is likely to be caused at the molecular level primarily by increased nitric oxide (NO) production or decreased inactivation of NO.
BACKGROUND
Physical training reverses endothelium dysfunction in patients with CHF, mediated by increased NO bioactivity. Some animal studies support a mechanism whereby training results in increased vascular NO levels by sustained transcriptional activation of the endothelial NO synthase (eNOS) gene, presumably due to shear stress. The mechanism has not been addressed in patients with CHF.
METHODS
The steady state transcript levels for eNOS and two other shear stress regulated genes (angiotensin-converting enzyme [ACE] and prostacyclin synthase [PGI2S]) were measured in samples of skeletal muscle from patients with CHF before and after 12 weeks of training. Transcript levels were measured in the same samples for two genes encoding antioxidant enzymes, copper zinc superoxide dismutase (Cu/Zn SOD) and glutathione peroxidase (GSH-Px). Untrained patients served as controls.
RESULTS
As expected, training significantly enhanced peak oxygen uptake in the patients with CHF. Training did not increase steady-state transcript levels for eNOS, ACE or PGI2S. In striking contrast, training increased the expression of the antioxidative enzyme genes by approximately 100%.
CONCLUSIONS
Our results do not support a model of benefit from training by increased eNOS expression. However, the data are entirely consistent with the alternative hypothesis, that reduced oxidative stress may account for the increase in vascular NO-mediated vasodilation. Insight into the mechanism may be relevant when considering therapies for exercise-intolerant patients with CHF.
| ||||||||||||||||||||||||||||||||
To address this issue for the first time in patients with CHF, we determined whether physical training affects the steady-state expression levels of eNOS or other genes that contain a shear-stress response regulatory cis-element (10) in skeletal muscle, including angiotensin-converting enzyme (ACE) and prostacyclin synthase (PGI2S). For comparison, we also analyzed transcript levels for copper zinc superoxide dismutase (Cu/Zn SOD) and glutathione peroxidase (GSH-Px), two antioxidative enzymes that metabolize oxygen free radicals and, thereby, increase NO activity indirectly. Our results do not support a model that patients with CHF benefit from training by sustained enhancement of eNOS expression due to vascular shear stress. However, the data are entirely consistent with the alternative hypothesis, that reduced oxidative stress could account for the increase in vascular NO-mediated vasodilation.
| Methods |
|---|
|
|
|---|
3 months duration were recruited for the study. Patients with angina, significant obstructive lung disease or significant peripheral arterial disease were excluded. Four patients remained sedentary and served as controls. Trained (T) and nontrained (NT) patients were the same age (T: 62 ± 6 vs. NT: 66 ± 6 years), received the same treatment and had the same clinical characteristics. All patients were New York Heart Association functional class III. The T group included four patients with nonischemic and six patients with ischemic cardiomyopathies; the NT group included two patients with nonischemic and two patients with ischemic cardiomyopathies. Mean left ventricular ejection fraction was comparable between the two groups (T: 34 ± 9% vs. NT: 27 ± 5%). Medical therapy for CHF consisted of furosemide and ACE inhibitors in all patients, digoxin in five patients, beta-adrenergic blocking agents in eight patients and long-acting oral nitrate preparations in one patient. All patients were clinically well-compensated at the time of the study, and their medical regimen did not change during the course of the study. The Ethical Review Board of the Albert Einstein College of Medicine approved the study. All patients gave written informed consent before the study. Training program. Patients exercised on a semirecumbent bicycle (Tunturi 803, Turku, Finland) at a work load corresponding to 50% of peak aerobic capacity for 45 min four times a week for a total of 12 weeks. Peak oxygen uptake was measured at six weeks, and the workload was remeasured to correspond to 50% of peak oxygen capacity.
Measurement of peak oxygen uptake. Patients performed a symptom-limited maximal treadmill exercise test using a modified Naughton protocol. Leg fatigue or dyspnea limited exercise. Peak oxygen uptake was determined as the average in the last 30 s of exercise when the respiratory exchange ratio was >1.0 using a breath-by-breath analysis of expired gases (Medical Graphics System 2001, Minneapolis, Minnesota). The peak volume of oxygen at baseline was the average of two values that were within 10%. Thereafter, only one single test was performed at 6 and 12 weeks.
Muscle biopsies. Muscle biopsies of the vastus lateralis were performed using a needle (Bard Monopty, Covington, Georgia). Biopsy samples were plunged into liquid nitrogen immediately and transferred to a freezer at 80°C until processed. Skeletal muscle biopsy could be performed at only two time points according to Institutional Review Board approval: 24 h before starting the training program and 48 h after the end of the training program.
Reverse transcription polymerase chain reaction (RT/PCR) analysis of skeletal muscle samples. RNA was prepared from tissue samples, complementary DNA (cDNA) generated by reverse transcription (RT) and specific products amplified by semiquantitative polymerase chain reaction (PCR), as described (11). All primers were designed to amplify fragments of cDNA spanning at least one intron (except those for Cu/Zn SOD, which lack introns). Polymerase chain reaction using mock RT reactions were conducted for all samples in order to exclude the presence of product derived from genomic DNA.
After PCR, products were separated by electrophoresis in 5% polyacrylamide nondenaturing gels. Phosphorimage analysis was performed with a Molecular Dynamics Storm 860 system (Sunnyvale, California) to quantify the relative levels of PCR products. Products were shown to accumulate linearly in accordance with cycle number and were directly dependent on the amount of RNA added to the RT reaction, determined by the ratio of products derived from samples using 0.25 or 0.5 µg RNA. The eNOS, PGI2S, ACE, Cu/Zn SOD and GSH-Px transcript levels were normalized to Von Willebrand factor (VWF) transcript in each case to control for inherent small differences in vasculature content from independent biopsies. This is necessary because it is likely that vascular endothelial mass increases during physical training. Acute changes in VWF transcription may occur during each training session, but that is not relevant nor is it reflected in our analysis.
PCR primers, product size and cycles used for semiquantitative RT/PCR. The PCR primers, product sizes and cycles used for semiquantitative RT/PCR were as follows:
Statistical analysis. Results are expressed as mean ± SEM. Differences between groups were assessed using a two-way analysis of variance with a Newman-Keuls adjustment for multiple groups. Significance was accepted at p < 0.05.
| Results |
|---|
|
|
|---|
For analysis of gene expression, RNA was prepared from vastus lateralis muscle biopsies taken from each patient before and after the training protocol, and steady-state eNOS transcript levels were measured using a semiquantitative RT-PCR assay performed under conditions that ensured a linear accumulation of product with respect to input RNA and cycle number. An example of data from one patient is shown in Figure 1, demonstrating the quantitative nature of the assay. Transcript levels were normalized in each case relative to those encoding VWF, as a marker for endothelial cells to account for inherent differences in vascular contribution within the biopsies. Therefore, we measured the relative amount of eNOS messenger RNA (mRNA) within a given amount of muscle vasculature for each patient. The data clearly demonstrate that there is no net increase in eNOS mRNA per unit vasculature after training (Fig. 2). The eNOS/VWF ratios were 0.55 ± 0.1 and 0.54 ± 0.08 before and after training, respectively. Similarly, there was no change in relative eNOS/VWF levels in the untrained control patients (0.46 ± 0.10 vs. 0.47 ± 0.06).
|
|
Therefore, we analyzed the relative transcript levels of genes encoding antioxidant enzyme by the same method. Transcript levels for these gene products were determined for each patient using the same RT reaction used to measure the shear-stress responsive genes (Fig. 3). In striking contrast with the previous results, mRNA ratios for both Cn/Zn SOD/VWF mRNA and GSH-Px/VWF were increased approximately 100% by physical training (Fig. 3) (0.69 ± 0.09 vs. 1.47 ± 0.22; 0.71 ± 0.09 vs. 1.29 ± 0.19, respectively). This increase per unit vasculature is highly significant (p < 0.05), while, in the control sedentary patients, Cu/Zn SOD and GSH-Px gene expression did not change (0.63 ± 0.09 vs. 0.66 ± 0.17; 1.95 ± 0.24 vs. 1.90 ± 0.16, respectively). We conclude that, in patients with CHF, physical training affects the expression of antioxidative enzyme genes in the skeletal muscle vasculature.
|
| Discussion |
|---|
|
|
|---|
Blunted NO-mediated vasodilation in patients with CHF could be caused by reduced NO synthesis or increased NO inactivation by reactive oxygen metabolites (17). Support for both mechanisms is provided by animal studies. For example, eNOS expression is reduced in the aorta of dogs that underwent one month of left ventricular pacing, indicating that the resulting left ventricular dysfunction may impair vascular NO synthesis (18). In the same pacing model, exercising 2 h per day for 10 consecutive days increased expression of eNOS in the aorta (5). Since the promoter for the eNOS gene contains a shear-stress responsive element (19), a likely possibility is that periodic increases in shear stress associated with physical training can result in sustained upregulation of eNOS gene expression. In a rat model of heart failure, impaired vascular endothelial function was attributed to enhanced vascular production of superoxide anion (9), and expression of eNOS was increased in the aorta of rats with heart failure when compared with that of rats without heart failure. The recent finding that H2O2 induces eNOS gene expression in endothelial cells and increases the stability of eNOS mRNA suggests that the increased oxidative stress that characterizes the syndrome of CHF may be, in part, responsible for eNOS production (20).
Decreased inactivation of NO after training may benefit patients with CHF. Our study is the first to investigate this complex issue in a clinical setting with respect to CHF patients and training. The data do not support a hypothesis that training benefits patients with CHF primarily by a mechanism of sustained increases in NO production. Steady-state transcript levels for the eNOS, ACE and PGI2S genes, which are all regulated at the transcriptional level by a shear-stress response element (21,22), were not altered in our patients after 12 weeks of physical training. Instead, we found significant changes in steady-state levels for genes encoding antioxidant enzymes, supporting the hypothesis that this mechanism may play an important role in providing benefit to patients with CHF. In fact, there was previously support for this mechanism from animal and human studies. In rats without heart failure, endurance training increases superoxide dismutase gene expression in skeletal muscle fibers with high oxidative metabolism (8). In healthy men, skeletal muscle superoxide dismutase activity correlates with maximum oxygen consumption attained during graded exercise (23). Presently, the mechanism by which physical training modulates antioxidative enzyme activity and gene expression is poorly understood. However, in cultured human aortic endothelial cells, shear stress modulates Cu/Zn SOD protein content, enzyme activity and gene expression (24). Whether periodic increases in shear stress associated with physical training are sufficient to upregulate Cu/Zn SOD expression in skeletal muscle remains to be demonstrated, but, based on our data, this is an intriguing possibility.
Limitations of the study and relevance to therapy.
Our conclusions are limited by the size of the study because only patients with CHF that could tolerate an extended exercise program were eligible. We would like to document whether there is a linear relationship between peak aerobic capacity and changes in gene expression, but statistically meaningful relationships cannot be obtained given the small changes in peak capacity and the small patient sample. Also, it will be important in the future to investigate protein levels and enzyme activities for the genes we tested, which was not possible using the small sample materials obtained for each patient by biopsy. However, the data provide clear evidence that a beneficial training program in patients with CHF results in increased basal levels of antioxidant genes and not stress-responsive genes, including eNOS. Our conclusion is supported by recently obtained data that activation of NF-
B is reduced in vascular endothelial cells from patients undergoing the equivalent of physical training (unpublished data). This may be of relevance for devising alternative therapeutic strategies for this patient population, which is generally intolerant to exercise. Thus, increased NO bioactivity resulting from decreased levels of reactive oxygen metabolites and, thereby, reduced NO inactivation is most likely responsible for the beneficial effect of physical training on vascular endothelial function in patients with CHF.
| Footnotes |
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
T. J. Vittorio, R. Zolty, M. E. Kasper, R. M. Khandwalla, D. S. Hirsh, C.-H. Tseng, U. P. Jorde, and K. Ahuja Differential Effects of Carvedilol and Metoprolol Succinate on Plasma Norepinephrine Release and Peak Exercise Heart Rate in Subjects With Chronic Heart Failure Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2008; 13(1): 51 - 57. [Abstract] [PDF] |
||||
![]() |
L. Gao, W. Wang, D. Liu, and I. H. Zucker Exercise Training Normalizes Sympathetic Outflow by Central Antioxidant Mechanisms in Rabbits With Pacing-Induced Chronic Heart Failure Circulation, June 19, 2007; 115(24): 3095 - 3102. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Spier, M. D. Delp, J. N. Stallone, J. M. Dominguez II, and J. M. Muller-Delp Exercise training enhances flow-induced vasodilation in skeletal muscle resistance arteries of aged rats: role of PGI2 and nitric oxide Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H3119 - H3127. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-a. Okabe, K. Shimada, M. Hattori, T. Murayama, M. Yokode, T. Kita, and C. Kishimoto Swimming reduces the severity of atherosclerosis in apolipoprotein E deficient mice by antioxidant effects Cardiovasc Res, June 1, 2007; 74(3): 537 - 545. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Ventura-Clapier, B. Mettauer, and X. Bigard Beneficial effects of endurance training on cardiac and skeletal muscle energy metabolism in heart failure Cardiovasc Res, January 1, 2007; 73(1): 10 - 18. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Jelic and T. H. Le Jemtel Diagnostic Usefulness of B-Type Natriuretic Peptide and Functional Consequences of Muscle Alterations in COPD and Chronic Heart Failure. Chest, October 1, 2006; 130(4): 1220 - 1230. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Couillard and C. Prefaut From muscle disuse to myopathy in COPD: potential contribution of oxidative stress Eur. Respir. J., October 1, 2005; 26(4): 703 - 719. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Fluck Hypoxaemia enhanced peripheral muscle oxidative stress in COPD Thorax, October 1, 2005; 60(10): 797 - 798. [Full Text] [PDF] |
||||
![]() |
T. Troosters, R. Casaburi, R. Gosselink, and M. Decramer Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., July 1, 2005; 172(1): 19 - 38. [Full Text] [PDF] |
||||
![]() |
A. Linke, V. Adams, P. C. Schulze, S. Erbs, S. Gielen, E. Fiehn, S. Mobius-Winkler, A. Schubert, G. Schuler, and R. Hambrecht Antioxidative Effects of Exercise Training in Patients With Chronic Heart Failure: Increase in Radical Scavenger Enzyme Activity in Skeletal Muscle Circulation, April 12, 2005; 111(14): 1763 - 1770. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J Green, A. Maiorana, G. O'Driscoll, and R. Taylor Effect of exercise training on endothelium-derived nitric oxide function in humans J. Physiol., November 15, 2004; 561(1): 1 - 25. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yamawaki, J. Haendeler, and B. C. Berk Thioredoxin: A Key Regulator of Cardiovascular Homeostasis Circ. Res., November 28, 2003; 93(11): 1029 - 1033. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Gielen, V. Adams, S. Mobius-Winkler, A. Linke, S. Erbs, J. Yu, W. Kempf, A. Schubert, G. Schuler, and R. Hambrecht Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure J. Am. Coll. Cardiol., September 3, 2003; 42(5): 861 - 868. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Mann and M. B. Reid Exercise training and skeletal muscle inflammation in chronic heart failure: feeling better about fatigue J. Am. Coll. Cardiol., September 3, 2003; 42(5): 869 - 872. [Full Text] [PDF] |
||||
![]() |
E. De Sousa, P. Lechene, D. Fortin, B. N'Guessan, S. Belmadani, X. Bigard, V. Veksler, and R. Ventura-Clapier Cardiac and skeletal muscle energy metabolism in heart failure: beneficial effects of voluntary activity Cardiovasc Res, November 1, 2002; 56(2): 260 - 268. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Maas, E. Schwedhelm, J. Albsmeier, and R. H Boger The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function Vascular Medicine, August 1, 2002; 7(3): 213 - 225. [Abstract] [PDF] |
||||
![]() |
R. Hambrecht, P. C. Schulze, S. Gielen, A. Linke, S. Mobius-Winkler, J. Yu, J.u. Kratzsch, G. Baldauf, M. W. Busse, A. Schubert, et al. Reduction of insulin-like growth factor-I expression in the skeletal muscle of noncachectic patients with chronic heart failure J. Am. Coll. Cardiol., April 3, 2002; 39(7): 1175 - 1181. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |